Glaucoma is the second-leading cause of blindness, affecting approximately 78 million people worldwide.1
Glaucoma is a chronic, irreversible condition that progresses slowly over time. It cannot be cured so treatment is aimed at slowing vision loss by managing intraocular pressure (IOP), which builds up within the eye and damages the optic nerve. Glaucoma treatment has traditionally required patients to use multiple types of prescription eye drops for the rest of their lives, and sometimes undergo complex and invasive eye surgery.
An entirely new class of surgery, call Micro-Invasive Glaucoma Surgery (MIGS), is helping to transform the treatment of glaucoma. The iStent® Trabecular Micro-Bypass Stent from Glaukos Corporation is the first and only MIGS device approved by the FDA. It is a powerful new option that doctors are using to control IOP for glaucoma patients everywhere.
1.) Market Scope 2014.